Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

BACKGROUND: Lenvatinib combined with pembrolizumab showed a promising result in an early phase study for hepatocellular carcinoma (HCC). The efficacy and safety of lenvatinib plus pembrolizumab for patients with unresectable HCC (uHCC) beyond the first-line setting were unclear. METHODS: Seventy-one...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chi-Jung, Lee, Pei-Chang, Hung, Ya-Wen, Lee, Chieh-Ju, Chi, Chen-Ta, Lee, I-Cheng, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519717/
https://www.ncbi.nlm.nih.gov/pubmed/35347395
http://dx.doi.org/10.1007/s00262-022-03185-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519717/
https://www.ncbi.nlm.nih.gov/pubmed/35347395
http://dx.doi.org/10.1007/s00262-022-03185-6

Ejemplares similares